Dr. Olivia Pagani – International Breast Cancer Study Group (IBCSG)
Five to ten years of adjuvant tamoxifen is the standard adjuvant endocrine therapy (ET) in premenopausal women with ER+ breast cancer, as it has been shown to result in substantial reduction of approximately 40% in both the risk of breast cancer recurrence and breast cancer-related death.
Women hoping to get pregnant after a 5 to 10 years course of ET may suffer from substantially reduced ovarian reserves and chance of conception. A pause of ET in this population has never been studied in a prospective manner. Thus in 2014, IBCSG launched the POSITIVE – a large international observational study to evaluate the safety of temporary interruption of endocrine therapy to allow pregnancy in ER+ breast cancer patients 42 years and younger.
The POSITIVE study has enrolled 518 premenopausal breast cancer patients who want to get pregnant despite receiving adjuvant endocrine therapy. This once-in-a-lifetime study was conducted in over 200 hospitals in 20 countries around the world with the aim of helping hundreds of thousands of young breast cancer patients worldwide fulfill their motherhood ambitions without putting their cancer outcome at risk.